Glaxosmithkline Pharmaceuticals informs about financial results

24 Jul 2018 Evaluate

Pursuant to Clause 33 read with Clause 30 of the SEBI Listing Obligations and Disclosure Requirements (LODR) Regulations, 2015, Glaxosmithkline Pharmaceuticals has informed about submission of the Un-Audited Standalone Financial Results and Limited Review Report for the first quarter ended 30th June 2018.

The above information is a part of company’s filings submitted to BSE.

Glaxosmithkline Phar Share Price

2308.00 28.15 (1.23%)
24-Mar-2026 16:01 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1756.80
Dr. Reddys Lab 1260.40
Cipla 1219.30
Zydus Lifesciences 887.00
Lupin 2331.75
View more..
Register Now to get our Free Newsletter & much more!

© 2026 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×